Objective The study aims to investigate the expression of ADGRL3 in glioma, and analyze its relationship to clinicopathological parameters and prognosis in glioma patients. Methods Bioinformatics database and tools were applied to analyze the expression of ADGRL3 in pan-cancer tissues, compare the different expression level between ADGRL3 in different grades glioma tissues, explore the relation of expression of ADGRL3 to clinicopathological parameters and survival of patients. In addition, GO enrichment analysis was used to analyze the interacting genes and proteins of ADGRL3 in the SRTING and GeneMANIA databases. Timer databases verified the correlation between ADGRL3 and immune cells mutually．Results ADGRL3 is highly expressed in various tumors, with significantly higher expression levels in low-grade gliomas and glioblastomas compared to other tumors. Its expression decreased with the increase of the grade of gliomas. The expression of ADGRL3 is correlated with multiple clinicopathological indicators. In low grade gliomas, patients with high ADGRL3 expression have better prognoses compared to those with low expression (P < 0.05). However, in glioblastomas, the expression level of ADGRL3 is not significantly correlated with patient prognosis (P > 0.05). Analysis in SRTING,GeneMANIA,and DAVID database found the interaction genes and proteins of ADGRL3 were enriched in signal transduction, protein homodimerization activity, neuron projection and other processes. The Timer database presented that ADGRL3 was correlated with the infiltration of CD8+ T cells in glioma. Conclusion ADGRL3 may be able to influence the occurrence，progression and prognosis of glioma and may serve as a biomarker for the prognosis of glioma patients．